AN ACUTE ORAL TOXICITY STUDY OF T-AYU-HM PREMIUM TABLET IN RATS: AN INITIATIVE FOR SICKLE CELL ANEMIA MANAGEMENT

Sickle cell anemia is a major life-threatening hemoglobin disorder in the world. This hemoglobin disorder is an autosomal recessive type, therefore considered as a major health problem in the world. The pain symptoms and complications of sickle cell anemia can be life-threatening many times. Management of sickle cell anemia demands drugs to be safe, well-tolerated, lesser side effects, and effective in improving the quality of life in patients. The alternative system of medicine can be the fruitful therapeutic option in conditions where the drug has to be consumed for life long. The T-AYU-HM Premium is a novel traditional Ayurvedic medicine designed on such a purpose to reduce clinical complications and enhance the quality of life in sickle cell anemia patients. The study conducted was a single dose oral toxicity study of T-AYU-HM Premium to assess its safety profile at a high dose. The study was conducted in compliance with the OECD principles of GLP (1998). The study was conducted according to OECD for testing of chemicals, N-425 acute oral toxicity Study–Up and Down Procedure. Various parameters, like mortality, clinical signs, and Bodyweight, were assessed. Results show that T-AYU-HM Premium is safe for greater than 5000 mg/kg body weight. No signs of mortality or clinical parameter changes were observed. No significant body weight changes were observed in the study. The results suggest that T-AYU-HM Premium might become a good therapeutic option for sickle cell anemia in the future.